Health and Social Care Committee

Availability of Orkambi on the NHS inquiry

Inquiry status: open

The Committee has received written submissions from NICE, NHS England and Vertex Pharmaceuticals, as can be seen in the correspondence published here. It has also published a number of other written submissions here. It took oral evidence from representatives of NHS England, NICE and Vertex Pharmaceuticals, as well as from representatives of patients and clinicians, on Thursday 7 March 2019.

The Committee is currently awaiting updates on the progress of ongoing negotiations between NHS England and Vertex Pharmaceuticals. Find the most recent updates below:

The Committee's response to the updates can be found here

Scope of the inquiry

The Committee’s inquiry into this area is currently concentrated on the provision and pricing of Orkambi, and other drugs developed by Vertex Pharmaceuticals for the treatment of cystic fibrosis. The Committee will be considering the positions taken in the ongoing negotiations between Vertex and NHS England, and NICE’s assessment of the cost-effectiveness of these drugs.


Latest evidence

  • 07 Mar 2019 - Availability of Orkambi on the NHS - oral evidence | PDF version (PDF379 KB) HC 1808 | Published 11 Mar 2019

    Evidence given by A patient representative nominated by the Cystic Fibrosis Trust, a clinician representative nominated by the Cystic Fibrosis TrustProfessor Stephen Powis, National Medical Director, John Stewart, National Director, Specialised Commissioning, NHS England, Sir Andrew Dillon, Chief Executive, Meindert Boysen, Director of the Centre for Health Technology Evaluation, NICEDr Jeff Leiden, Chairman, President and Chief Executive Officer, Stuart A. Arbuckle, Executive Vice President and Chief Commercial Officer, Vertex Pharmaceuticals

    Watch this evidence session

Next meeting(s)

There are currently no public meetings scheduled.

Receive RSS updates

Share this page